Κατεύθυνση Παθοβιολογία Στόματος
Βιβλιοθήκη Οδοντιατρικής

2015-05-13

2015

Γάτου Ευστρατία

Ουρανία Νικολάτου-Γαλίτη Καθηγήτρια Νοσοκομειακής Οδοντιατρικής, Οδοντιατρική Σχολή, ΕΚΠΑ, Αικατερίνη Δοντά-Μπακογιάννη Αναπληρώτρια Καθηγήτρια Διαγνωστικής και Ακτινολογίας Στόματος, Οδοντιατρική Σχολή, ΕΚΠΑ, Δήμος Καλύβας Αναπληρωτής Καθηγητής Στοματικής και Γναθοπροσωπικής Χειρουργικής, Οδοντιατρική Σχολή, ΕΚΠΑ

Μελέτη του βαθμού ξηροστομίας και της ποιότητας ζωής σε ασθενείς με καρκίνο κεφαλής/τραχήλου που έχουν υποβληθεί σε ακτινοθεραπεία ή χημειοακτινοθεραπεία

Greek

Objectives: The aim of this study was to evaluate the degree of xerostomia and
long-term quality of life (QoL) in head and neck cancer patients who received
radiotherapy or chemoradiotherapy.
Materials and Methods: Patients treated for head and neck cancer after
radiotherapy or chemoradiotherapy were included in the study. Demographic and
clinical data concerning stage, tumor site and treatment information were
recorded. The subjective grade of xerostomia was evaluated by a 100-mm visual
analogue scale (VAS). QoL was assessed using the quality-of-life core
questionnaire EORTC QLQ-C30 and the head and neck module EORTC QLQ-H&N35.
Results: Twenty-three patients with a mean age of 60.2 years were assessed.
Oral cavity (39.1%) and nasopharynx (26.1%) were the most common tumor sites.
Mean total radiotherapy dose was 66.04 Gray. Chemotherapy was administered to
87% of patients. The mean follow-up time following the completion of
radiotherapy was 18.9 months.
The majority of patients (95.6%) complained of xerostomia with mean VAS score
49.74. Mild, moderate and severe xerostomia was reported by 30.4%, 47.8% and
17.4% of the patients, respectively.
The mean score for the Global Health Status/QoL was 67.17 and the mean scores
in functional scales ranged from 76.08 to 86.44. The most disturbing symptoms
were fatigue (27.05) (QLQ-C30) and dry mouth (65.21), sticky saliva (57.97) and
less sexuality (42.1) (QLQ-H&N35).
There were significant (p<0.05) correlations between VAS score of xerostomia
and Global Health Status/QoL (-0.485), social functioning (-0.479), fatigue
(0.442), pain (0.465), swallowing (0.420), trouble with social eating (0.483)
and dry mouth (0,570) (Spearman correlation).
Conclusions: Xerostomia is common in head and neck cancer radiotherapy or
chemoradiotherapy and significantly affects patients’ quality of life. These
findings emphasize the importance of interventions for prevention or treatment
of post-radiotherapy xerostomia.

Head and neck cancer, Xerostomia, Quality of life, EORTC QLQ-C30, EORTC QLQ-H&N35

No

0

Yes

258

167

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1315329